首页> 外文期刊>Integrative cancer therapies >Synergistic and additive effects of modified citrus pectin with two polybotanical compounds, in the suppression of invasive behavior of human breast and prostate cancer cells
【24h】

Synergistic and additive effects of modified citrus pectin with two polybotanical compounds, in the suppression of invasive behavior of human breast and prostate cancer cells

机译:修饰的柑橘果胶与两种多植物化合物的协同作用和加和作用,抑制人乳腺癌和前列腺癌细胞的侵袭行为

获取原文
获取原文并翻译 | 示例
           

摘要

Aim. The objective of this study was to evaluate the combined effect of a known galectin-3 inhibitor, PectaSol-C modified citrus pectin (MCP), and 2 novel integrative polybotanical compounds for breast and prostate health, BreastDefend (BD) and ProstaCaid (PC), on invasive behavior in human breast and prostate cancer cells in vitro, respectively. Methods. The effect of MCP and BD and of MCP and PC on invasiveness was assessed by cell adhesion, cell migration, and cell invasion assays. Secretion of urokinase plasminogen activator (uPA) was determined by Western blot analysis. Results. Although low concentrations of MCP (0.25-1.0 mg/mL) do not suppress cell adhesion of breast or prostate cancer cells, the combination of MCP with BD or PC synergistically inhibits adhesion of these cells. Dose-dependent inhibition of breast and prostate cancer cell migration by MCP (0.25-1.0 mg/mL) is synergistically enhanced by BD (20 μg/mL) and PC (10 μg/mL), respectively. BD or PC did not further inhibit the invasion of breast and prostate cancer cells by MCP; however, the combination of MCP with BD or PC suppressed secretion of uPA from breast and prostate cancer cells, respectively. Conclusion. The combination of MCP with BD and of MCP with PC synergistically inhibits the metastatic phenotypes of human breast and prostate cancer cells, respectively. Further studies confirming these observations in animal models of breast and prostate cancer metastasis are warranted.
机译:目标。这项研究的目的是评估已知的galectin-3抑制剂,PectaSol-C修饰的柑橘果胶(MCP)和2种新型的综合性多植物化合物对乳房和前列腺健康的综合作用,Beast BreefDefend(BD)和ProstaCaid(PC)分别针对人类乳腺癌和前列腺癌细胞的体外侵袭行为。方法。 MCP和BD以及MCP和PC对侵袭性的影响通过细胞粘附,细胞迁移和细胞侵袭试验进行评估。通过蛋白质印迹分析确定尿激酶纤溶酶原激活物(uPA)的分泌。结果。尽管低浓度的MCP(0.25-1.0 mg / mL)不会抑制乳腺癌或前列腺癌细胞的细胞粘附,但MCP与BD或PC的组合可协同抑制这些细胞的粘附。 BD(20μg/ mL)和PC(10μg/ mL)分别协同增强了MCP(0.25-1.0 mg / mL)对乳腺癌和前列腺癌细胞迁移的剂量依赖性抑制作用。 BD或PC不能进一步抑制MCP对乳腺癌和前列腺癌细胞的侵袭。然而,MCP与BD或PC的组合分别抑制了乳腺癌和前列腺癌细胞中uPA的分泌。结论。 MCP与BD的组合以及MCP与PC的组合分别协同抑制人乳腺癌和前列腺癌细胞的转移表型。进一步的研究证实了在乳腺癌和前列腺癌转移的动物模型中的这些观察结果是必要的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号